| Today's News and Trends | Will a coronary drug-coated balloon finally gain full approval from the FDA? New data presented at TCT 2023 seems to suggest it just might happen. Will a coronary drug-coated balloon finally gain full approval from the FDA? New data presented at TCT 2023 seems to suggest it just might happen. | |
| The first-place finish earned HeartPoint Global $20,000 in prize money. The first-place finish earned HeartPoint Global $20,000 in prize money. | |
| | All eyes were on TAVR during the first round of late-breaking clinical trials at TCT 2023 in San Francisco. Researchers shared key updates related to devices from Edwards Lifesciences, Medtronic, Boston Scientific and JenaValve Technology. All eyes were on TAVR during the first round of late-breaking clinical trials at TCT 2023 in San Francisco. Researchers shared key updates related to devices from Edwards Lifesciences, Medtronic, Boston Scientific and JenaValve Technology. | |
| The Aurora EV-ICD MRI SureScan is similar in size and shape to traditional ICDs, but it is implanted outside of the patient’s heart and veins. The Aurora EV-ICD MRI SureScan is similar in size and shape to traditional ICDs, but it is implanted outside of the patient’s heart and veins. | |
| Ziad Ali, MD, discusses the mixed results of the ILUMIEN IV trial comparing OCT vs angiography alone. Ziad Ali, MD, discusses the mixed results of the ILUMIEN IV trial comparing OCT vs angiography alone. | |
| | Robert Hendel, MD, discussed everything from declining reimbursements in cardiology to prior authorization policies in an exclusive new interview. Robert Hendel, MD, discussed everything from declining reimbursements in cardiology to prior authorization policies in an exclusive new interview. | |
| Researchers hopes this first-in-class gene therapy, known as TN-201, can restore the patient’s MYBPC3 levels and eventually lead to disease reversal. Researchers hopes this first-in-class gene therapy, known as TN-201, can restore the patient’s MYBPC3 levels and eventually lead to disease reversal. | |
| | “Physicians everywhere—across every state and specialty—continue to carry tremendous burdens that have us frustrated, burned out, abandoning hope," said AMA President Jesse Ehrenfeld. “Physicians everywhere—across every state and specialty—continue to carry tremendous burdens that have us frustrated, burned out, abandoning hope," said AMA President Jesse Ehrenfeld. | |
| The ratings agency dropped Akumin from "CCC" to "D," the lowest mark on S&P’s scale, typically used after a company files such a petition. The ratings agency dropped Akumin from "CCC" to "D," the lowest mark on S&P’s scale, typically used after a company files such a petition. | |
| |
|
| | |
|